Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

61.06 +0.19 (+0.31%)

Streaming Delayed Price Updated: 2:49 PM EST, Feb 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Robert F. Kennedy Jr.'s Vaccine Shake-Up Sparks Coast-To-Coast Divide: West Coast Creates Health Alliance, Florida Rolls Back Requirements ↗

September 04, 2025

California, Oregon and Washington form regional vaccine alliance to counter federal guidance under Robert F. Kennedy Jr. as Florida eliminates state mandates.

Via Benzinga

Florida Chooses 'Medical Freedom' As State Plans To End Vaccine Mandates, Even For Schools: Experts Warn Of 'Major Disaster' ↗

September 04, 2025

Florida plans to end all statewide vaccine mandates, even those required for school attendance, framing the move as a defense of individual liberties, which has since received pushback from public...

Via Benzinga

Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Why ↗

September 03, 2025

Via Stocktwits

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday? ↗

September 03, 2025

Wave Life Sciences shares early WVE-006 trial results in alpha-1 antitrypsin deficiency, reporting durable protein production and favorable safety.

Via Benzinga

What's Driving the Market Sentiment Around GSK? ↗

September 03, 2025

Via Benzinga

GSK Secures UK Approval For First New Oral Antibiotic In 30 Years To Treat Resistant Urinary Tract Infections ↗

August 27, 2025

Via Stocktwits

Price Over Earnings Overview: GSK ↗

August 27, 2025

Via Benzinga

What Does the Market Think About GSK? ↗

August 07, 2025

Via Benzinga

Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds ↗

September 02, 2025

Upstream Bio's Phase 2 trial of verekitug in chronic rhinosinusitis met all endpoints, showing reduced nasal polyps, congestion, and need for surgery.

Via Benzinga

Bernie Sanders Demands Health Secretary RFK Jr.'s Resignation As CDC Leadership Crisis Deepens ↗

August 30, 2025

Senator Bernie Sanders called for HHS Secretary RFK Jr.'s resignation over his anti-vaccine policies, ousting of CDC Director Susan Monarez.

Via Benzinga

Elizabeth Warren Slams Trump's CDC Purge: Calls Out RFK Jr's Statements On Measles Vaccines — 'These Fools Can't Be Trusted With Your Health' ↗

August 29, 2025

Sen. Elizabeth Warren (D-Mass.) is sounding the alarm on President Donald Trump's attempts at overhauling leadership at the Centers for Disease Control and Prevention, warning of risks to public...

Via Benzinga

Topics Government

Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study ↗

August 21, 2025

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Via Benzinga

How Is The Market Feeling About GSK? ↗

July 31, 2025

Via Benzinga

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

US FDA Reviewers Highlight Safety Concerns With GSK’s Investigational Cancer Drug: Retail’s On The Fence ↗

July 15, 2025

Via Stocktwits

CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans ↗

August 21, 2025

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Via Benzinga

Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗

July 31, 2025

Via Stocktwits

Topics Government

GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth ↗

July 30, 2025

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.

Via Benzinga

GSK Expects Full-Year Earnings At Top End Of Guidance: CEO Says ‘Confident In Our Long-Term Outlooks’ ↗

July 30, 2025

GSK now expects turnover growth to be toward the top end of 3% to 5% and core earnings per share growth to be closer to 8% at constant exchange rate.

Via Stocktwits

Topics Artificial Intelligence World Trade

After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact ↗

July 28, 2025

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion.

Via Benzinga

GSK's Blood Cancer Drug Review Extended As FDA Seeks More Data ↗

July 24, 2025

FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.

Via Benzinga

GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning ↗

July 18, 2025

FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of July 23 PDUFA decision.

Via Benzinga

Dow Futures Edge Higher As Strong Earnings Boost Investor Confidence: AXP, NFLX, IBKR, GSK Among Stocks To Watch ↗

July 18, 2025

While Dow Jones futures were up 0.07% at the time of writing, the S&P 500 futures were up 0.03%.

Via Stocktwits

Topics ETFs Economy Government

GSK’s Blenrep Underwhelms FDA Panel Over Dose Risk-Benefit Balance In Myeloma; Retail Traders Stay Optimistic ↗

July 18, 2025

Despite the setback, GSK defended the drug’s potential, citing strong results from DREAMM trials.

Via Stocktwits

GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults ↗

July 15, 2025

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.

Via Benzinga

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? ↗

July 14, 2025

BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating.

Via Benzinga

GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance ↗

July 14, 2025

A decision by the FDA on the new submission is expected in the first half of 2026.

Via Stocktwits

Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony ↗

July 11, 2025

Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal standards by the trial judge.

Via Benzinga

Topics Lawsuit

GSK Stock Gains As Flu Vaccine Rollout Begins And US Recovers From Most Severe Season In 15 Years ↗

July 10, 2025

Fluarix and Flulaval are being shipped in single-dose, 0.5 mL pre-filled syringes and are not recommended for individuals with severe allergies to vaccine components or a history of Guillain-Barré...

Via Stocktwits

Topics Death Lawsuit

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma ↗

July 08, 2025

The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.